26
|
Abstract
SummaryTwo new cases of congenital dysfibrinogenemia have been discovered. In the first case, “Fibrinogen TROYES”, the abnormality is characterized by a prolonged thrombin clotting time, the defect being due to abnormal aggregation of fibrin monomers. There is no tendency towards excessive bleeding. The abnormality is found to be present with the same intensity in one of the patient’s brothers and one of his sisters.In the second case, “Fibrinogen METZ”, the abnormality is more pronounced, since, even in the presence of very high thrombin concentrations no clotting occurs. The abnormality is due to a defect in the release of fibrinopeptides, on addition of thrombin. The patient’s blood contains only abnormal fibrinogen. The plasma recalcification time is more prolonged than in the whole blood clotting time. The abnormality is present in both parents in heterozygote form, a milder form than in the patient who is homozygous. The patient has a moderate bleeding tendency, the parents being normal in this respect.
Collapse
|
27
|
Soria J, Soria C, Samama M, Josso F. Présence d’un Antigène Plasmatique Indispensable à la Stabilisation de la Fibrine dans Deux Cas de Déficit Congénital en Facteur XIII. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1654245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
RésuméL’étude d’un immun sérum anti-facteur XIII montre que celui-ci est bien capable de neutraliser l’activité stabilisante de la fibrine du plasma.Le plasma de deux sujets ayant un déficit en facteur XIII a été étudié au moyen de cet anti-sérum par différentes méthodes: immuno-électrophorèse, inhibition de l’hémagglutination passive, neutralisation de l’inhibition par l’immunsérum de l’activité biologique du facteur XIII.Dans le plasma de ces deux patients, l’antigène spécifique de l’immunsérum étudié a été retrouvé à un taux normal.Ces résultats sont compatibles avec deux hypothèses: ou bien il s’agit chez ces patients, non pas d’un déficit quantitatif mais d’une anomalie structurale du facteur XIII le privant de son activité biologique ; ou bien un deuxième facteur protéique est nécessaire à la stabilisation de la fibrine, facteur qui serait absent chez nos deux malades.
Collapse
|
28
|
Fontcuberta J, Soria J. Reply to: Factor XII levels, factor XII 46 C>T polymorphism and venous thrombosis: a word of caution is needed. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
29
|
Almasy L, Borrell M, Stone W, Blanco-Vaca F, Soria J, Blangero J, Fontcuberta J, Souto J. Thromboplastin-thrombomodulin-mediated Time and Serum Folate Levels Are Genetically Correlated with the Risk of Thromboembolic Disease: Results from the GAIT Project. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1612945] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe GAIT (Genetic Analysis of Idiopathic Thrombophilia) Project is a family-based study dedicated to elucidating the genetic basis of hemostasis-related phenotypes and thrombosis risk. In this paper, we have examined several lesser-studied hemostasis-related phenotypes in the 21 GAIT families: levels of vitamin B12, serum folate, whole blood folate, α 2-antiplasmin, prekallikrein, β2-glycoprotein I, soluble P-selectin, factor XIII A and B subunits and a new coagulation measurement based on thromboplastin time in the presence or absence of thrombomodulin. Using the variance component method, we estimated the relative contributions of genetic and environmental influences on these phenotypes. In addition, we calculated the genetic correlations between thrombosis risk and each of these phenotypes.All 12 phenotypes showed significant genetic contributions with genes accounting for 22% to 78% of the variance after correction for covariate effects. Four phenotypes (three traits involving thromboplastin-thrombomodulin mediated coagulation time and serum folate) exhibited significant genetic correlations with thrombosis. Thus, some of the genes that influence quantitative variation in these physiological phenotypes also influence the risk of thrombosis.The high heritabilities and significant genetic correlations between thrombosis and some risk factors suggest that joint consideration of correlated quantitative phenotypes will aid in identifying susceptibility genes.
Collapse
|
30
|
Soria J, Guandalino M, Vedrine N, Pereira B, Guy L. [Results of conservative surgical management of ureteral injuries]. Prog Urol 2017; 28:120-127. [PMID: 29162380 DOI: 10.1016/j.purol.2017.10.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Revised: 10/13/2017] [Accepted: 10/20/2017] [Indexed: 11/30/2022]
Abstract
INTRODUCTION The ureter is a retroperitoneal organ. Ureteral injuries are rare, with a prevalence of 0.083% of surgical interventions over 10 years. The objective of this study was to evaluate the surgical management of ureteric injuries according to the time of discovery, their size and their location. We also evaluated the results of this management on the renal repercussion as well as the predictive factors of the severity of the ureteric injuries. MATERIAL AND METHODS This was a monocentric retrospective study carried out on the basis of a systematic review of the CHU surgery files. RESULTS The average follow-up was 30 months. The average hospital stay was 8 days. Thirty-four patients (73.9%) underwent initial endoscopic management by attempting a double J probe. Only 20 patients received this double J probe and only 11 patients (55%) did not recidivate the ureteral injury with a median duration of maintenance of the double J probe of 90 days (28-240). Thirty-five patients received open surgical management (76.1%). We found 57% ureterovesical reimplantations (n=20), corresponding to pelvic ureteral injuries (n=32). We also found 20% of nephrectomies. No patient had recurrence of the ureteral injury. Eight patients had secondary dilatation of the pyelocalicious cavities (28.57%). The success of surgical treatment was therefore 57%. CONCLUSION The management of surgically treated ureter injuries provides good results but remains relatively diversified due to the different lesion levels. It was effective in 57% of cases including nephrectomies as failure of treatment. LEVEL OF EVIDENCE 4.
Collapse
|
31
|
Solomon B, Soria J, Blackhall F, Shaw A, Camidge D, Kim D, Mok T, Fernandez-Banet J, Kan Z, Li S, Liu Y, Ho S. P1.01-016 Next-Generation Sequencing Shows Mechanisms of Intrinsic Resistance in ALK-Positive NSCLC Patients Treated with Crizotinib. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
Mezquita L, Auclin E, Charrier M, Ferrara R, Caramella C, Planchard D, Ponce S, Paz-Ares L, Audigier-Valette C, Tessonnier L, Martinez G, Zalcman G, Lahmar J, Remon J, Adam J, Chaput N, Soria J, Besse B. MA 05.03 The Early Monitoring of Derived Neutrophil-To Lymphocyte Ratio (dNLR) Could Be a Surrogate Marker of Benefit of Immunotherapy in NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.480] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Boucher M, Mezquita L, Auclin E, Mons M, Marghadi J, Charrier M, Ferrara R, Planchard D, Anas G, Le Pechoux C, Botticella A, Caramella C, Adam J, Soria J, Besse B. P2.01-038 Determinants of Frailty and Treatment Toxicity in Non-Small Cell Lung Cancer Patient. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Ferrara R, Caramella C, Texier M, Audigier-Valette C, Tessonnier L, Mezquita L, Lahmar J, Mazieres J, Zalcman G, Brosseau S, Westeel V, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Champiat S, Fertè C, Planchard D, Boucher M, Martinez-Bernal G, Bria E, Tortora G, Soria J, Besse B. MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.541] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Mezquita L, Auclin E, Ferrara R, Caramella C, Charrier M, Remon J, Planchard D, Ponce S, Paz-Ares L, Lahmar J, Leroy L, Audigier-Valette C, Zeron-Medina J, Garrido P, Zalcman G, Mazieres J, Adam J, Chaput N, Soria J, Besse B. P2.07-060 Response Assessment and Subgroups Analysis According to the Lung Immune Prognostic Index (LIPI) for Immunotherapy in Advanced NSCLC Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
36
|
Guandalino M, Soria J, Vedrine N, Guy L, Khene Z, Peyronnet B, Bosquet E, Freton L, Grafeille V, Pradere B, Verhoest G, Rioux-Leclercq N, Mathieu R. Plaies urétérales traitées chirurgicalement. Étude monocentrique rétrospective. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Henon C, Mezquita L, Auclin E, Ammari S, Caramella C, Le Pechoux C, Botticella A, Planchard D, Gazzah A, Ferrara R, Lahmar J, Martinez-Bernal G, Adam J, Soria J, Besse B. P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.11.064] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
38
|
Goss G, Felip E, Cobo M, Lu S, Syrigos K, Lee K, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel S, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria J. P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1484] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
39
|
Mezquita L, Jovelet C, Ngocamus M, Auclin E, Remon J, Green E, Plagnol V, Morris C, Gazzah A, Caramella C, Adam J, Lacroix L, Friboulet L, Soria J, Besse B, Planchard D. MA 11.01 Liquid Biopsies for Monitoring BRAF Mutation (V600E) in Advanced BRAF (V600E) Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.542] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Mok T, Johnson M, Garon E, Peters S, Soria J, Wang L, Jarkowski A, Dennis P, Zhou C. P1.04-008 POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.867] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Buzzatti G, Allorant A, Verlingue L, Brandao D, Massard C, Hollebecque A, Ferté C, Lacroix L, Ngo-Camus M, Auger N, Scoazec J, Ammari S, Gazzah A, Planchard D, Besse B, Solary E, André F, Michiels S, Soria J, Menis J. Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Rodríguez L, Castillo O, Soria J, Melin P, Valdez F, Gonzalez CI, Martinez GE, Soto J. A fuzzy hierarchical operator in the grey wolf optimizer algorithm. Appl Soft Comput 2017. [DOI: 10.1016/j.asoc.2017.03.048] [Citation(s) in RCA: 141] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Petrov L, Soria J, Cataluna R. Influence of Copper on the Catalytic Activity of Supported Rhodium Catalysts in the Reactions of CO Oxidation and NO Reduction. EURASIAN CHEMICO-TECHNOLOGICAL JOURNAL 2017. [DOI: 10.18321/ectj543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
<p>The catalytic activity of Cu, Rh, and Rh/Cu, catalysts supported on Al<sub>2</sub>O<sub>3</sub>, CeO<sub>2</sub> and CeO<sub>2</sub>/Al<sub>2</sub>O<sub>3</sub> in reactions of CO oxidation and NO reduction has been studied in temperature-programmed regime. Addition of Cu to Rh catalysts decreases temperature at which 5 and 50% degree of conversion, while end of reaction temperature is not influenced by presence of Cu. The presence of Cu has positive effect on the activity of Rh containing catalysts in the low temperature region. Cu has noticeable promoting effect mainly for the catalytic activity in the reaction of CO oxidation and in smaller extent for the reaction of NO reduction. Preliminary redox treatment of the catalysts decreases the light off temperature in the reactions of CO oxidation and in NO reduction. Thermal treatment at temperatures up to 973 K does not have sensible effect on the catalytic activities of all studied catalysts. Calcination at 1073 K, however, strongly decreases the catalytic activity of Rh/Cu/CeO<sub>2</sub>/Al<sub>2</sub>O<sub>3</sub> catalysts.</p>
Collapse
|
44
|
Sanz J, Sobrados I, Soria J, Yurdakal S, Augugliaro V. Anatase nanoparticles boundaries resulting from titanium tetrachloride hydrolysis. Catal Today 2017. [DOI: 10.1016/j.cattod.2016.06.052] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Pasticier G, Lee JW, Crouzet S, Soria J, Medollima C, Mege-Lechevallier F, Chapelon JY, Rouviere O, Gelet A. Localized prostate cancer and salvage treatment: EBRT first + salvage HIFU or HIFU first + salvage EBRT? A single-institution matched pair analysis over a 20-year period. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.6_suppl.77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
77 Background: In the field of curative treatment for localized prostate cancer, HIFU (High Intensity Focused ultrasound) is one of salvage option after EBRT(external beam radiation therapy) failure and EBRT is the standard salvage option for local relapse after HIFU.Our aim was to compare and evaluate the oncologic outcomes between HIFU first + salvage EBRT versus EBRT first +salvage HIFU. Methods: Using a matched pair analysis, 342 Patients (171 in each group) treated between 1994 and 2014 in the same institution were prospectively followed and matched to a 1:1 basis. Outcome measurements: Overall Survival Rate(OSR), cancer specific(CSSR) and metastasis free (MFSR) survival rates were the primary endpoints. Secondary endpoints were survival rate free of hormone therapy (HTFR) and the rate of side effects Clavien score ≥ 3. Results: Mean follow-up were 114 and 124 months for HIFU+ S-EBRT and EBRT + S-HIFU respectively. At 7 years from the primary treatment , the MFSR were significantly better after HIFU first +S- EBRT than after EBRT first+S- HIFU: 96% vs 91%% (p:0.011). The OSR and the CSSR were not significantly different in the two arms (97% and 99% after HIFU+S- EBRT versus 96% and 98% after EBRT+S- HIFU). The HTFR at 7 years was significantly different (p <0.001) after HIFU+ S-EBRT than after EBRT+ S-HIFU 90% versus 69%. In multivariable Cox regression, the initial Gleason sum ≥ 8 and the treatment strategy were predictors of MFSR (risk ratio 3.2 for treatment modality). The rate of side effect Clavien score≥ 3 was significantly higher (p:0.01) in the EBRT+ S-HIFU arm than in the HIFU+ S-EBRT arm. The rate of urinary toxicity (severe incontinence and bladder outlet obstruction) were worse in the EBRT+ S-HIFU arm than in HIFU+S-EBRT arm: 9.4% and 15.2% vs 1.2% and 7.6% (p:0.01 and 0.078). Conclusions: In this single-institution Matched Pair comparison, the MFSR and HTFR were significantly better in the HIFU+S-EBRT arm than in the EBRT+S-HIFU arm. The rate of urinairy toxicity and Clavien≥3 side-effects were Higher in the EBRT + S-HIFU arm than in the HIFU + S-EBRT arm.
Collapse
|
46
|
Shah S, Fourgeaud C, Derieux S, Mirshahi S, Soria J, Contant G, Pimi C, Lo Dico R, Eveno C, Ullah M, Kaci R, Pocard M, Mirshahi M. The close relationship between heparanase and epithelial mesenchymal transition related fibrosis in gastric signet-ring cell adenocarcinoma. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30338-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
47
|
Lee J, Crouzet S, Soria J, Gal J, Melo-de-Lima C, Pommier P, Badet L, Gelet A. Radiothérapie externe de rattrapage (SRTE) après high intensity focused ultrasound (HIFU) versus HIFU de rattrapage (SHIFU) après radiothérapie externe (RTE) dans la récidive locale du cancer de prostate : analyse des résultats oncologiques et des complications. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
48
|
Prieto-Torres L, Gracia Cazaña T, Pastushenko I, Morales Moya A, Soria J, Ara Martín M. Dermatosis ampollosa hemorrágica a distancia por enoxaparina: un efecto secundario infrecuente en paciente oncológica anticoagulada. Semergen 2016; 42:504-506. [DOI: 10.1016/j.semerg.2015.09.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Revised: 09/22/2015] [Accepted: 09/23/2015] [Indexed: 11/27/2022]
|
49
|
Suárez T, Soria J, Chatard-Baptiste C. Osmoprotective activity of alpha-lipoic acid and taurine on hyperosmolar stress in cultured human corneal and conjunctival epithelial cells. Acta Ophthalmol 2016. [DOI: 10.1111/j.1755-3768.2016.0387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
50
|
Fourgeaud C, Derieux S, Mirshahi S, Besbes S, Chidiac J, Mahé I, Contant G, Pocard M, Soria J, Mirshahi M. PO-23 - Expression of heparanase in cancer as biomarker of malignancies: overexpression in an aggressive, poor survival gastric cancer "gastric signet ring cell carcinoma" compared with that of other gastric cancers. Thromb Res 2016; 140 Suppl 1:S184-5. [PMID: 27161709 DOI: 10.1016/s0049-3848(16)30156-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
INTRODUCTION Gastric signet ring cell carcinoma (GSRC) is a distinct entity among of other gastric cancer. With unknown etiopathology, their incidence is increasing and it presents a low sensitivity to chemotherapy. AIM Here, we studied the expression of the heparanase (HPA) in cancer tissues from GSRC patients and several cancer cell lines. HPA is an endo-β-D-glucuronidase, capable of cleaving the lateral chains of heparan sulfate on cell surfaces and the extracellular matrix at acidic pH. Apart from its well-characterized enzyme activity, HPA also has independent enzymatic functions, such as up-regulation of vascular endothelial growth factor (VEGF) -A and VEGF-C and activation of intracellular signaling pathways involved in, survival, migration and proliferation of tumor cells. It can also induce an hypercoagulability by a non-enzymatic manner. MATERIALS AND METHODS HPA was tested in several cancer cell lines from ovaries (OVCAR-3, SKOV-3), breast (MDAMB231, MCF7) colon (LS-174), lung (A549), uterus (HELA) and gastric (adenocarcinoma (AGS) and GSRC (KATO-III) using several techniques such as RT-PCR, Q-PCR, immunocytochemistry, flow cytometry and degradation of Fondaparinux at pH 5, evaluated by its anti Xa activity evaluated by Factor Xa amidolytic activity. The amount of HPA mRNA in the biopsy simples of gastric adenocarcinoma (n=10) and GSRC (n=11) in tumors and their environment were analyzed. RESULTS HPA gene is expressed in all cancer cell lines, but its level varies depending on the tumor cell line. In biopsies of gastric cancer, the HPA gene is more expressed in the tumor regions (p=0.0002) and tumor environment (p=0.015) in GSRC than in gastric adenocarcinoma. B) The activity of HPA, evaluated by degradation of Fondaparinux at pH 5, 1) in the supernatants of 10(6) cancer cells: the residual activity of Fondaparinux after 2 hours incubation at 37°C with OVCAR-3 supernatant was of 70% of control value, and of 80% with KATO-III cell supernatants. 2) in patient's plasmas, this technique cannot be used because the site of degradation of fondaparinux by heparanase is masked by AT present in plasma. CONCLUSIONS Heparanase was found in in many cancer cell lines and its level depends on origin of tumor cells and on its aggressivity. Taking into account the pro-metastatic functions, proangiogenic and procoagulant activity of HPA and its overexpression in gastric signet ring cell carcinoma of poor prognosis and its cell line, HPA can be considered as a biomarker of malignancy and as a therapeutic target in GSRC patients.
Collapse
|